PLoS one

Low Immune Response to Hepatitis B Vaccine among Children in Dakar, Senegal

Marie-Anne Rey-Cuille[1,2], Abdoulaye Seck[3], Richard Njouom[4], Loïc Chartier[1], Housseyn Dembel Sow[5], MamadouBa[5], Amadou Sidy Ka[6], Mohamadou Njankouo[4], Dominique Rousset[4], Tamara Giles-Vernick[1], Guillemette Unal[1], Jean-Marie Sire[3,7], Benoît Garin[3], François Simon[7], Muriel Vray[1,8]*

1 Unité de Recherche et d'Expertise en Epidémiologie des Maladies Emergentes, Institut Pasteur, Paris, France, 2 Institut des Sciences Biologiques, CNRS, Paris, France, 3 Laboratoire de Biologie Médicale, Institut Pasteur, Dakar, Sénégal, 4 Service de Virologie, Centre Pasteur du Cameroun, Yaoundé, Cameroun, 5 Hôpital d'Enfants Albert Royer, Dakar, Sénégal, 6 Service de Pédiatrie, Hôpital Principal, Dakar, Sénégal, 7 Département de virologie, Hôpital Saint Louis, Paris, France, 8 Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France

Abstract

HBV vaccine was introduced into the Expanded Programme on Immunization (EPI) in Senegal and Cameroon in 2005. We conducted a cross-sectional study in both countries to assess the HBV immune protection among children. All consecutive children under 4 years old, hospitalized for any reason between May 2009 and May 2010, with an immunisation card and a complete HBV vaccination, were tested for anti-HBs and anti-HBc. A total of 242 anti-HBc-negative children (128 in Cameroon and 114 in Senegal) were considered in the analysis. The prevalence of children with anti-HBs ≥10 IU/L was higher in Cameroon with 92% (95% CI: 87%–97%) compared to Senegal with 58% (95% CI: 49%–67%), (p<0.001). The response to vaccination in Senegal was lower in 2006–2007 (43%) than in 2008–2009 (65%), (p = 0.028). Our results, although not based on a representative sample of Senegalese or Cameroonian child populations, reveal a significant problem in vaccine response in Senegal. This response problem extends well beyond hepatitis B: the same children who have not developed an immune response to the HBV vaccine are also at risk for diphtheria, tetanus, pertussis (DTwP) and *Haemophilus influenzae* type b (Hib). Field biological monitoring should be carried out regularly in resource-poor countries to check quality of the vaccine administered.

Introduction

The prevalence of HBV chronic infection is particularly high in Sub Saharan Africa, ranging from 7 to 26% [1]. Because available treatment for hepatitis B virus infection does not provide a complete cure and is very costly in developing countries, prevention remains crucial [2]. Previous studies have demonstrated immunogenicity of HBV vaccine ranging between 88% and 94% with anti-HBs response ≥10 mUI/ml, associated (pentavalent vaccine) or not with diphtheria-tetanus-pertussis (DTwP) and *Haemophilus influenzae* type b (Hib) [3,4,5,6]. In 1991, the World Health Organization recommended that all countries introduce hepatitis B vaccination into their routine national infant immunisation programmes [7].

In Senegal, previous studies have demonstrated an HBV chronic infection prevalence of 17% among blood donors [8], a prevalence of HBV exposure of 60% among children between 0 and 5 years old [9], and 14 % of HBsAg positivity among pregnant women [10]. In Cameroon, the prevalence of HBsAg varies from 12% among Pygmies [11] to 20% among children of primary school age [12] and 25 % among a population older than 4 years of age [13]. In response to WHO recommendations, Cameroon and Senegal integrated the HBV vaccination into the

Expanded Programme on Immunization (EPI) in 2005. The DTwP-HBV-Hib combination vaccine Zilbrix™ developed by GSK is currently used by the National Programme of Cameroon, while Quinvaxem™, a DTwP-HBV-Hib vaccine co-developed by Crucell and Novartis, is administered in Senegal. Both combination vaccines have been shown to be immunogenic and well tolerated [5,14]. The three doses of the pentavalent vaccine are administrated at 6, 10 and 14 weeks of age in both countries, according to WHO recommendations. With the introduction and expansion of the HBV vaccine in sub-Saharan Africa, it remains imperative to monitor the seroprotective response to HBV childhood immunisation programmes.

We conducted a cross-sectional study in Senegal and Cameroon in order to assess the response to vaccination among children with a complete HBV vaccination.

Results

A total of 242 children with an immunisation card were recruited, 128 in Cameroon, and 114 in Senegal (Table 1). Forty-seven percent of children were female, and the overall median age was 15 months [9;21]. Senegal presented a higher prevalence of children suffering from moderate or severe malnutrition (66%),

compared to Cameroon (12%), (p<0.001). The main causes of the children's hospitalization were gastro-intestinal infections and infectious syndromes in Cameroon (60%), and gastro-intestinal infections and respiratory diseases in Senegal (60%). The median [IQR] delays between the first and the second dose of the HBV vaccination and between the second and the third dose were 30 days [28; 35] and 31 days [28; 35] in Cameroon, and 32 days [30; 35] and 33 days [31; 36] in Senegal, respectively. The prevalence of children with anti-HBs ≥10 IU/L was higher in Cameroon, with 92% (95% CI: 87%–97%) compared to Senegal, with 58% (95% CI: 49%–67%), (p<0.001). The proportion of children with anti-HBs ≥100 IU/L was 66% and 23% in Cameroon and Senegal, respectively (p<0.001) (Table 1).

In the two countries, the children were recruited in two hospitals and no differences were revealed in the percentages of responders. The Cameroon hospitals showed 95% (Essos Hospital) versus 87% (Chantal Biya Foundation) responding (p = 0.17), whereas the Senegal hospitals indicated 56% (Albert Royer Paediatric Hospital) versus 65% (Hôpital Principal) responding (p = 0.48) (data not shown).

Taking into account the year of vaccination, we found that in Senegal, the response to vaccination was lower in 2006–2007 (43%), compared with 2008–2009 (65%), (p = 0.028).

In contrast, in Cameroon, no difference existed between the prevalence of children anti-HBs+ during these two time periods (96% versus 91%, p = 0.69) (Figure 1).

Nutritional status was significantly correlated with response to the HBV vaccination (p<0.001), with 85% of children protected (anti-HBs ≥10 IU/L) among those with normal nutrition status versus 60 % of children with moderate to severe malnutrition. The percentages of protected children were lower in the two countries among the children with moderate or severe malnutrition (12% vs 20% in Cameroon, 62% vs 71% in Senegal). However, the nutritional status was not significant when adjusted for the country of residence (Table 2).


Figure 1. Immune response (anti-HBs levels) to complete HBV vaccination according to the year of vaccination in Cameroon and Senegal among children with immunization card.
doi:10.1371/journal.pone.0038153.g001

Discussion

Overall, we note that the immunization schedule was well respected for all children in both countries, with a median time between doses close to 30 days.

While we observed in Cameroon a protection rate of 92%, corresponding with previously reported protection rates for hepatitis B vaccination in both developing and developed countries [3,4,5], we were surprised by the low protection level (58%) in Senegal. Moreover, in Senegal, the proportion of children responding to the vaccine varied dramatically over time with a low protected rate in 2006–2007 (43%).

Table 1. Characteristics of the children.

Variables	Cameroon N = 128	Senegal N = 114	Total N = 242	p
Sex, female N (%)	55(43)	59 (52)	114 (47)	0.17
Age (months)*	13 [9;20]	17 [11; 24]	15 [9;21]	0.004
Moderate or severe malnutrition (**WAZ-score ≤−2**) N (%)	**15 (12)**	**75 (66)**	**90 (38)**	<0.001
Reasons for hospitalisation N (%)				<0.001
Gastro-intestinal infection	34 (27)	33 (29)	67 (28)	
Respiratory Infection	19 (15)	35 (31)	54 (22)	
Malaria	16 (13)	2 (2)	18 (7)	
Other Infectious Syndrome	**42 (33)**	13 (11)	55 (23)	
Other reasons (convulsions, anaemia, malnutrition)	17 (13)	**31 (27)**	48 (20)	
Delay of the HBV vaccination (days)*				
Between the first and the second dose	30 [28; 35]	32 [30; 35]	32 [28;35]	0.001
Between the second and the third dose	31 [28; 35]	33 [31; 36]	32 [29; 35]	0.008
Anti-HBs N (%)				
≥10 IU/L	118 (92)	66 (58)	184 (76)	<0.001
≥100 IU/L	85 (66)	26 (23)	111 (46)	<0.001

*Median [Q1; Q3].
doi:10.1371/journal.pone.0038153.t001

Table 2. Factors associated with HBV vaccine response.

	Anti-HBs		Univariate analysis		Multivariate analysis	
Variables	<10 IU/L N = 58	≥10 IU/L N = 184	OR (CI$_{95\%}$)	p	OR (CI$_{95\%}$)	p
Country N (%)						
Cameroon	10 (17)	118 (64)	1		1	
Senegal	48 (83)	66 (36)	0.1 (0.06–0.2)	<0.001	0.1 (0.06–0.3)	<0.001
Sex, female N (%)	23 (40)	91 (49)	1.5 (0.8–2.7)	0.19		
Age ≤15 months N (%)	17 (29)	108 (59)	3.4 (1.8–6.5)	<0.001	3.1 (1.6–6.1)	0.001
Moderate or severe malnutrition N (%)	36 (62)	54 (31)	0.3 (0.1–0.5)	<0.001		

Faced with these unexpected results, we sought to verify the hypothesis of lower vaccine immunogenicity, by measuring the response to the diphtheria antigens associated in the same vial. Antibodies against diphtheria antigens persist several months after vaccination [15]. In the present study, the detection of antibodies was performed using EIA (IgG testkit, Genzyme, Germany) in nineteen blood samples from Senegalese children vaccinated less than one year after vaccination: nine responder children (anti-HBs+) and ten vaccinated and non-responder children (anti-HBs–). Low anti-diphtheria antibody response was significantly associated with the lack of anti-HBs antibodies (p = 0.036), but the low value of correlation (r = 0.48) impaired any definitive conclusion. The low value of the coefficient between anti-diphtheria and anti-HBs antibodies is probably due to the small number of cases.

Several possible explanations may account for these results. First, there may exist problems with storage conditions in Senegal, since frequent power outages may provoke lapses in backup electrical systems and compromise the cold chain [16]. Second, there may be a quality problem with the pentavalent Quinvaxem^{TM} (Crucell) vaccine. In 2011, for instance, Quinvaxem production temporarily ceased because of sterilisation problems [17]. A third explanation may be related to children's nutritional status, which is much more severe among Senegalese children than among Cameroonian children. The small number of children with moderate or severe malnutrition in our study, especially in Cameroon, led to the result that when both variables (nutritional status and country) were introduced simultaneously in a multivariate model, only country remained significantly associated with antibody response. However, the percentages of protected children were lower in the two countries among those children with moderate or severe malnutrition. These results are in accordance with recent studies that reported no immune response difference between healthy children and those with compromised nutritional status [18,19,20,21].

Although we cannot definitively explain the reason(s) for anti-HBV vaccination failure in Senegal, the striking disparity between our results, based on anti-HBs antibody levels, and vaccination card registrations demonstrates a critical need for monitoring accurately vaccine delivery and coverage. Current vaccination coverage surveys are based mainly on an assessment of immunisation cards [22]. Yet our results, although not based on a representative sample of Senegalese or Cameroonian child populations, reveal a significant problem in vaccine response in Senegal that present official surveys cannot detect. This response problem may extend well beyond hepatitis B: the same children who have not developed an immune response to the HBV vaccine are also at risk for diphtheria, tetanus, pertussis and *Haemophilus influenzae* B.

Current evaluations of vaccination programmes, particularly in resource-poor countries, necessitate supplemental and regular biological monitoring, to ensure vaccine quality and storage and to verify that vaccine recipients are genuinely protected. We would also call for further studies on larger populations in countries that participate in the EPI, so as to investigate more fully the vaccines and their storage and delivery. These results make evidence the need for collaboration between the Expanded Programme on Immunization and national programmes to control Hepatitis B. Such measures should constitute a clear global public health priority.

Materials and Methods

Study population

This study took place from May 2009 to May 2010, in two hospitals in Yaounde (Cameroon), the Essos Hospital and the Chantal Biya Foundation, and in two hospitals in Dakar (Senegal), the Hôpital Principal and the Albert Royer Paediatric Hospital.

All consecutive children, under 4 years old, hospitalized for any reason, with a blood sample prescribed during hospitalisation, sufficiently healthy to withstand an extended blood sample of 2 ml minimum, with an immunisation card and a complete HBV vaccination including the three injections according to the recommended schedule (first dose 6 weeks after birth and intervals between 2 injections of 30 days minimum) and anti-HBc-negative were considered in this analysis.

Ethical approvals

Approval to conduct the study was obtained from the National Ethics Committee and the Ministry of Public Health of Cameroon and the National Comity of the Research in Health of Senegal. All children anti-HBs-negative and anti-HBc-negative were invited to return to receive an HBV vaccination free of charge, no matter the HBV vaccination status reported on their immunization card.

Data collection

Demographic and socioeconomic characteristics (age, sex, weight, and reason for hospitalization), vaccination records and all serological data were collected through a structured questionnaire.

Anthropometric measurements

Malnutrition status was estimated by the weight-for-age Z-score (WAZ), because most values for the children's height were missing.

WAZ was calculated using the Centers for Disease Control and Prevention 2000 child growth charts (CDC-2000) [23]. Moderate or severe malnutrition was defined when the WAZ value was less or equal to -2.

HBV markers

All samples were tested for anti-HBs and anti-HBc by enzyme immunoassay (EIA) (DiaSorin Biomedica, Sallugia, Italy). Anti-HBs antibodies were expressed in international units (IU/L). The level of anti-HBs of 10 IU/L and higher was considered to be seroprotective. The responders were defined as children anti-HBs+ and anti-HBc$-$, while the non responders were defined as children anti-HBs$-$ and anti-HBc$-$.

Diphtheria antibodies

The detection of antibodies against diphtheria was performed using EIA (IgG testkit, Genzyme, Germany). Levels of anti-diphtheria antibodies were expressed in international units (IU/ml). All sera with a level of anti-diphtheria of 0.1 UI/ml and higher were considered to be positive.

Statistical analysis

Quantitative variables were expressed as median [Q1–Q3] and qualitative as percentages.

Anti-HBs antibodies were analysed using three categories: <10 IU/L, 10–99 IU/L, and ≥ 100 IU/L. The HBV immune response was measured taking into account the time of vaccination, 2006–2007 or 2008–2009, in the two countries. Univariate analysis was based on the chi2 test or Fisher's exact test for discrete variables and the Mann-Whitney test for continuous variables. For the multivariate analysis, quantitative variables were categorized around the median. All baseline variables associated with vaccine response in the univariate analysis ($p \leq 0.25$) were included in a backward stepwise logistic regression model. Interactions between factors associated with vaccine response and participating country (Senegal and Cameroon) were tested. Results were considered statistically significant when $p < 0.05$. Correlation between anti-diphtheria antibody response and anti-HBs antibodies was based on the Spearman coefficient and linear regression. STATA 11 software was used for all statistical analyses.

Author Contributions

Conceived and designed the experiments: ASK BG DR FS JMS LC MR MV RN. Performed the experiments: AS BG MN RN. Analyzed the data: DR FS JMS LC MR MV. Contributed reagents/materials/analysis tools: AS BG DS GU MB MN RN SK. Wrote the paper: BG LC MR MV TG. Designed the study and drafted the protocol: DR FS JMS MR MV. Set up study sites and enrolled participants to the study: AS DR MN GU JMS RN. Provided statistical expertise: LC. Participated in the analysis and interpretation of the results: FS SM. Drafted the manuscript: MR TGV MV. Contributed and approved the submission: MR AS RN LC HDS MB ASK MN DR TGV GU JMS BG FS MV. The guarantor: MV.

References

1. Andre F (2000) Hepatitis B epidemiology in Asia, the Middle East and Africa. Vaccine 18 Suppl 1: S20–22.
2. Lavanchy D (2005) Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 34 Suppl 1: S1–3.
3. Coursaget P, Deciron F, Tortey E, Barin F, Chiron JP, et al. (1984) Immune response to hepatitis B vaccine in infants and newborns: control trial in an endemic area (Senegal). IARC Sci Publ. pp 319–335.
4. Aspinall S, Kocks DJ (1998) Immunogenicity of a low-cost hepatitis B vaccine in the South African Expanded Programme on Immunisation. S Afr Med J 88: 36–39.
5. Gatchalian S, Reyes M, Bernal N, Lefevre I, David MP, et al. (2005) A new DTPw-HBV/Hib vaccine is immunogenic and safe when administered according to the EPI (Expanded Programme for Immunization) schedule and following hepatitis B vaccination at birth. Hum Vaccin 1: 198–203.
6. Tsebe KV, Burnett RJ, Hlungwani NP, Sibara MM, Venter PA, et al. (2001) The first five years of universal hepatitis B vaccination in South Africa: evidence for elimination of HBsAg carriage in under 5-year-olds. Vaccine 19: 3919–3926.
7. WHO (1991) WHO expanded Programme on Immunisation. Report of the 14th global Advisory Group.: WHO/EPI/GEN/92.91.
8. Vray M, Debonne JM, Sire JM, Tran N, Chevalier B, et al. (2006) Molecular epidemiology of hepatitis B virus in Dakar, Senegal. J Med Virol 78: 329–334.
9. Sall Diallo A, Sarr M, Fall Y, Diagne C, Kane MO (2004) [Hepatitis B infection in infantile population of Senegal]. Dakar Med 49: 136–142.
10. Roingeard P, Diouf A, Sankale JL, Boye C, Mboup S, et al. (1993) Perinatal transmission of hepatitis B virus in Senegal, west Africa. Viral Immunol 6: 65–73.
11. Foupouapouognigni Y, Mba SA, Betsem a Betsem E, Rousset D, Froment A, et al. (2011) Hepatitis B and C virus infections in the three Pygmy groups in Cameroon. J Clin Microbiol 49: 737–740.
12. Chiaramonte M, Stroffolini T, Ngatchu T, Rapicetta M, Lantum D, et al. (1991) Hepatitis B virus infection in Cameroon: a seroepidemiological survey in city school children. J Med Virol 33: 95–99.
13. Garrigue G, Merlin M, Durand JP, Josse R, Kollo B, et al. (1985) [Prevalence of markers of viral hepatitis B in northern Cameroon]. Bull Soc Pathol Exot Filiales 78: 883–889.
14. Kanra G Fau - Kara A, Kara A Fau - Demiralp O, Demiralp O Fau - Contorni M, Contorni M Fau - Hilbert AK, Hilbert Ak Fau - Spyr C, et al. Safety and immunogenicity of a new fully liquid DTPw-HepB-Hib combination vaccine in infants.
15. Plotkin SA, Orenstein WA, Offit PA (2008) Vaccines: Elsevier-Saunders.
16. Wamukonya N (2005) Power sector reforms in sub-Saharan Africa: some lessons. Economic and Political Weekly 40: 5302–5308.
17. WHO (2010) Immunization standards, Vaccine quality. Available: http://www.who.int/immunization_standards/vaccine_quality/quinvaxem_shipment_nov10/en/. Accessed: 2012, May 5.
18. Dao H, Delisle H, Fournier P (1992) Anthropometric status, serum prealbumin level and immune response to measles vaccination in Mali children. J Trop Pediatr 38: 179–184.
19. el-Gamal Y, Aly RH, Hossny E, Afify E, el-Taliawy D (1996) Response of Egyptian infants with protein calorie malnutrition to hepatitis B vaccination. J Trop Pediatr 42: 144–145.
20. Lakshmi G, Reddy RP, Kumar KK, Bhavani NV, Dayanand M (2000) Study of the safety, immunogenicity and seroconversion of a hepatitis-B vaccine in malnourished children of India. Vaccine 18: 2009–2014.
21. Moore SE, Goldblatt D, Bates CJ, Prentice AM (2003) Impact of nutritional status on antibody responses to different vaccines in undernourished Gambian children. Acta Paediatr 92: 170–176.
22. WHO (2010) Immunization surveillance, assessment and monitoring. Available: http://www.who.int/immunization_monitoring/en/. Accessed: 2012, May 5.
23. Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, et al. (2002) 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11: 1–190.